Zobrazeno 1 - 10
of 183
pro vyhledávání: '"Arlene, Chan"'
Autor:
Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, Angela DeMichele, Paolo Tarantino, Evandro de Azambuja, Georg Pfeiler, Miguel Martin, Justin M. Balko, Zbigniew Nowecki, Marija Balic, Adam M. Brufsky, Arlene Chan, Patrick G. Morris, Tufia Haddad, Sibylle Loibl, Yuan Liu, Lidija Soelkner, Christian Fesl, Erica L. Mayer, Michael Gnant, on behalf of the PALLAS groups and investigators
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-10 (2024)
Abstract Background Bidirectional crosstalk between HER2 and estrogen receptor (ER) pathways may influence outcomes and the efficacy of endocrine therapy (ET). Low HER2 expression levels (HER2-low) have emerged as a predictive biomarker in patients w
Externí odkaz:
https://doaj.org/article/c4f4965043a847fba7a786c64cdbe554
Autor:
Maya Asami Takagi, Simone T. Rhodes, Jun Hwan Kim, Maxwell King, Stephanie Soukar, Chad Martin, Angela Sasaki Cole, Arlene Chan, Ciara Brennan, Stephen Zyzanski, Barry Kissoondial, Neli Ragina
Publikováno v:
Vaccines, Vol 12, Iss 7, p 787 (2024)
Background: The COVID-19 pandemic has exacerbated existing healthcare disparities among American Indian/Alaska Native (AI/AN) populations rooted in historical traumas and systemic marginalization. Methods: This study conducted at a single Indian Heal
Externí odkaz:
https://doaj.org/article/9daac28d266e4e728f86fd47ff6e5a4a
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 8278-8288 (2023)
Abstract The importance of the immune microenvironment in triple negative and HER2‐amplified breast cancer (BC) is well‐established; less is known about the immune environment in luminal breast cancers. We aimed to assess for the impact of immune
Externí odkaz:
https://doaj.org/article/10b3700d6bc843a7ba23ff71e8df4db4
Autor:
Arlene Chan, Manuel Ruiz-Borrego, Gavin Marx, A. Jo Chien, Hope S. Rugo, Adam Brufsky, Michael Thirlwell, Maureen Trudeau, Ron Bose, José A. García-Sáenz, Daniel Egle, Barbara Pistilli, Johanna Wassermann, Kerry A. Cheong, Benjamin Schnappauf, Dieter Semsek, Christian F. Singer, Navid Foruzan, Daniel DiPrimeo, Leanne McCulloch, Sara A. Hurvitz, Carlos H. Barcenas
Publikováno v:
Breast, Vol 67, Iss , Pp 94-101 (2023)
Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for HER2-positive early-stage and metastatic breast cancer. Diarrhea is the most frequent side effect and the most common reason for early discontinuation. The phase
Externí odkaz:
https://doaj.org/article/59dce946fa4342e6b9fbbf464f2e5a40
Publikováno v:
Breast, Vol 68, Iss , Pp 239-240 (2023)
Externí odkaz:
https://doaj.org/article/53d294054f164779b2f52369824fbe31
Autor:
Peter A. Fasching, J. Thaddeus Beck, Arlene Chan, Michele De Laurentiis, Francisco J. Esteva, Guy Jerusalem, Patrick Neven, Xavier Pivot, Giulia V. Bianchi, Miguel Martin, David Chandiwana, Brad Lanoue, Antonia Ridolfi, Yingbo Wang, Karen Rodriguez Lorenc, Arnd Nusch
Publikováno v:
Breast, Vol 54, Iss , Pp 148-154 (2020)
Purpose: In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer, ribociclib plus fulvestrant significantly improved progression-free survival (PFS) and
Externí odkaz:
https://doaj.org/article/a5b481e9a0e5458182d897e58fbb782f
Autor:
Alberto Ocaña, Jose Ignacio Chacón, Lourdes Calvo, Antonio Antón, Mauro Mansutti, Joan Albanell, María Teresa Martínez, Ainhara Lahuerta, Giancarlo Bisagni, Begoña Bermejo, Vladimir Semiglazov, Marc Thill, Arlene Chan, Serafin Morales, Jesús Herranz, Ignacio Tusquets, Massimo Chiesa, Rosalía Caballero, Pinuccia Valagussa, Giampaolo Bianchini, Emilio Alba, Luca Gianni
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
BackgroundDerived neutrophil-to-lymphocyte ratio (dNLR) is a biomarker associated with clinical outcome in breast cancer (BC). We analyzed the association of dNLR with pathological complete response (pCR) in triple-negative BC (TNBC) patients receivi
Externí odkaz:
https://doaj.org/article/5764dcbf60e64458b2696da8d2eff802
Autor:
Stephen K. L. Chia, Miguel Martin, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gunter von Minckwitz, Janine Mansi, Carlos H. Barrios, Michael Gnant, Zorica Tomašević, Neelima Denduluri, Robert Šeparović, Sung-Bae Kim, Erik Hugger Jakobsen, Vernon Harvey, Nicholas Robert, John Smith, Graydon Harker, Bo Zhang, Lisa D. Eli, Yining Ye, Alshad S. Lalani, Marc Buyse, Arlene Chan
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Abstract Background Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disea
Externí odkaz:
https://doaj.org/article/cf5037433d854254a48613d85af66f77
Autor:
Frankie A. Holmes, Beverly Moy, Suzette Delaloge, Stephen K.L. Chia, Bent Ejlertsen, Janine Mansi, Hiroji Iwata, Michael Gnant, Marc Buyse, Carlos H. Barrios, Tajana Silovski, Robert Šeparović, Anna Bashford, Angel Guerrero Zotano, Neelima Denduluri, Debra Patt, Erhan Gokmen, Ira Gore, John W. Smith, Sibylle Loibl, Norikazu Masuda, Zorica Tomašević, Katarina Petráková, Daniel DiPrimeo, Alvin Wong, Miguel Martin, Arlene Chan
Publikováno v:
European Journal of Cancer. 184:48-59
ExteNET showed that neratinib, an irreversible pan-HER tyrosine ki- nase inhibitor, given for 1 year after trastuzumab-based therapy significantly improved inva- sive disease-free survival in women with early-stage HER2-positive breast cancer. We rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f52b3f56c3541c7f92ad50e9e346cad
https://doi.org/10.1016/j.ejca.2023.02.002
https://doi.org/10.1016/j.ejca.2023.02.002
Autor:
Arlene Chan, Daphne Day, Rina Hui, Nicole McCarthy, Rosalind Wilson, Demiana Faltaos, Morena Shaw, Caitlin Murphy
Publikováno v:
Cancer Research. 83:P3-07
Background: OP-1250 is a small molecule oral complete estrogen receptor antagonist (CERAN) that binds the ligand binding domain of the ER and completely blocks ER-driven transcriptional activity. CDK4/6 inhibitors in combination with endocrine therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d41f285d79aeb774c3a994db453fd47
https://doi.org/10.1158/1538-7445.sabcs22-p3-07-15
https://doi.org/10.1158/1538-7445.sabcs22-p3-07-15